In response to the nationwide shortage of ranitidine and other H2 antagonists, BOPA have produced a guideline on the use of H2 antagonists for the prevention and management of hypersensitivity to assist with clinical decision making.
Click here to view the guideline.
We are also planning a national service evaluation to monitor the impact of the shortage – details to follow soon. Watch this space!
We’re delighted to share that the BOPA abstracts presented at the 28th Annual BOPA Conference have now been published in the Journal of Oncology Pharmacy Practice. Huge congratulations to everyone…
BOPA welcomes the National Cancer Plan and highlights the essential role of cancer pharmacy professionals in delivering world‑class cancer care – The National Cancer Plan for England: delivering world class…
Open Letter to UK Pharmacists, Pharmacy Technicians and Pharmacy Trainees and Students Through an open letter published on its website, the UK Pharmacy Professional Leadership Advisory Board is inviting…
Join NCODA in Dublin, Ireland from 11-12 March for the 2026 NCODA Global Oncology & Haematology Congress — a new international meeting designed to unite leaders in oncology, hematology, diagnostics, and technology for two days of…
The 29th BOPA Annual Conference in 2026 will be held at the ICC London Olympia on 2-4 October 2026.
Check out the latest information here: Latest Conference 2026 – BOPA
Everything you need to know
